LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-19. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
This delivery method gained worldwide recognition during COVID-19 pandemic with the approval of mRNA vaccines from Pfizer-BioTech and Moderna. The rapid rollout of these vaccines proved that LNPs are not only effective but also scalable for mass production and global use. Looking beyond vaccines, mRNA therapies are now being explored for a range of therapeutic applications including cancer immunotherapy, genetic disorders, and other infectious diseases. Researchers are also testing alternative delivery systems, like exosomes and new types of nanoparticles, to make mRNA therapies safer and more efficient. However, challenges remain, as mRNA is highly sensitive to environmental conditions. To address this, ongoing research is expanding into new administration routes including inhalable or oral mNRA formulations. This could reduce production costs and make these therapies more accessible to the world.
== Technology == Dr. Werner Baumgartner was responsible for founding Psychemedics and spearheading its initial research. A nationally recognized expert on drug testing through hair samples, Dr. Baumgartner gained acclaim by procuring some strands of hair from the 19th-century poet John Keats. Despite the age of the hair, Baumgartner was able to detect that the poet, who died at the age of 26 from tuberculosis, had been taking an increasing amount of opium before his death, most likely used in painkillers. Dr. Baumgartner's find created a minor sensation, enough to warrant a mention in a 1985 Time magazine cover story about drugs in the workplace. After years of research proved that drugs deposited in the hair can be accurately measured, the company was formed in 1987 and pioneered the use of hair testing in commercial markets including banks, manufacturers, retailers, mining operations, hotels and casinos. The technology capitalizes on the way the body metabolizes ingested drugs as they flow through the blood stream and deposit in the cortex of the hair. Hair is stable and the deposits are permanently embedded in the hair, so hair acts like a tape recorder — “recording” drug deposits in proportion to use over time as drugs are deposited in proportion to use. Hair grows at approximately the rate of ½ an inch per month and takes about 5 days to grow out past the external layer of skin. Psychemedics’ standard test uses a 1 ½ inch sample of head hair, which provides an approximate 3 month history of drug use. Body hair can also be collected if head hair is not available.
The condensation between Crotonaldehyde (1) and dimethylamine (2) give dimethylaminobutadiene [139943-10-5] (3). The Diels-Alder reaction with ethyl atropate [22286-82-4] (4) yields a mixture of isomers, of which only the (E)-(trans)-isomers are active. The separation from the mixture by precipitation of the inactive (Z)-(cis)-isomers as zinc complex. The inactive (Z)-(cis)-isomers may be epimerized to the more thermodynamically favored (E)-(trans)-isomers via reflux in diluted phosphoric acid.
Sources: en.wikipedia.org
In most of Asia, several Sub-Saharan Africa and Pacific markets, rice based side dishes are often sold. In Greece and Bulgaria, potato wedges are sold instead of French fries. In a number of Eastern European locations and Portugal, beer is offered in addition to soft drinks. In 2023 KFC branches in UK and Ireland introduced new 'signature fries' (fries coated in herbs and spice) in an attempt to improve the taste of the fries.
=== G protein-coupled receptor inverse agonists === Two known endogenous inverse agonists are the Agouti-related peptide (AgRP) and its associated peptide Agouti signalling peptide (ASIP). AgRP and ASIP appear naturally in humans and bind melanocortin receptors 4 and 1 (Mc4R and Mc1R), respectively, with nanomolar affinities. The opioid antagonists naloxone and naltrexone act as neutral antagonists of the mu opioid receptors under normal conditions, but as inverse agonists when chronic exposure to opioids has increased the basal activity of the mu opioid receptors. 6α-naltrexo, 6β-naltrexol, 6β-naloxol, and 6β-naltrexamine acted neutral antagonists regardless of opioid binding and caused significantly reduced withdrawal jumping when compared to naloxone and naltrexone. Nearly all antihistamines acting at H1 receptors and H2 receptors have been shown to be inverse agonists. The beta blockers carvedilol and bucindolol have been shown to be low level inverse agonists at beta adrenoceptors.
== Further reading == Beck, M. T.; Kauffman, G. B. (1985). "COS and C3S2: The Discovery and Chemistry of Two Important Inorganic Sulfur Compounds". Polyhedron. 4 (5): 775–781. doi:10.1016/S0277-5387(00)87025-4. J. Elliott Campbell; Jürgen Kesselmeier; Dan Yakir; Joe A. Berry; Philippe Peylin; Sauveur Belviso; Timo Vesala; Kadmiel Maseyk; Ulrike Seibt; Huilin Chen; Mary E. Whelan; Timothy W. Hilton; Stephen A. Montzka; Max B. Berkelhammer; Sinikka T. Lennartz; Le Kuai; Georg Wohlfahrt; Yuting Wang; Nicola J. Blake; Donald R. Blake; James Stinecipher; Ian Baker; Stephen Sitch (2017). "Assessing a New Clue to How Much Carbon Plants Take Up". EOS. 98. doi:10.1029/2017EO075313. hdl:10871/31921. Svoronos P. D. N.; Bruno T. J. (2002). "Carbonyl sulfide: A review of its chemistry and properties". Industrial & Engineering Chemistry Research. 41 (22): 5321–5336. doi:10.1021/ie020365n.
Sources: en.wikipedia.org
In the next stage of the war, the French drove Russian forces out of Poland and employed many Polish and German soldiers in several sieges in Silesia and Pomerania, with the assistance of Dutch and Italian soldiers in the latter case. Napoleon then turned north to confront the remainder of the Russian army and to try to capture the temporary Prussian capital at Königsberg. A tactical draw at Eylau (7–8 February 1807), followed by capitulation at Danzig (24 May 1807) and the Battle of Heilsberg (10 June 1807), forced the Russians to withdraw further north. Napoleon decisively beat the Russian army at Friedland (14 June 1807), following which Alexander had to make peace with Napoleon at Tilsit (7 July 1807). In Germany and Poland, new Napoleonic client states, such as the Kingdom of Westphalia, Duchy of Warsaw, and Republic of Danzig, were established. By September, Marshal Guillaume Brune completed the occupation of Swedish Pomerania, allowing the Swedish army to withdraw with all its munitions of war.
=== MeSH D12.644.400 – neuropeptides === MeSH D12.644.400.070 – angiotensins MeSH D12.644.400.070.075 – angiotensin i MeSH D12.644.400.070.078 – angiotensin ii MeSH D12.644.400.070.080 – angiotensin iii MeSH D12.644.400.085 – bombesin MeSH D12.644.400.090 – bradykinin MeSH D12.644.400.095 – calcitonin MeSH D12.644.400.097 – calcitonin gene-related peptide MeSH D12.644.400.100 – carnosine MeSH D12.644.400.105 – cholecystokinin MeSH D12.644.400.120 – corticotropin MeSH D12.644.400.125 – corticotropin-releasing hormone MeSH D12.644.400.200 – delta sleep-inducing peptide MeSH D12.644.400.235 – fmrfamide MeSH D12.644.400.250 – galanin MeSH D12.644.400.275 – galanin-like peptide MeSH D12.644.400.300 – gastric inhibitory polypeptide MeSH D12.644.400.315 – gastrin-releasing peptide MeSH D12.644.400.320 – gastrins MeSH D12.644.400.340 – glucagon precursors MeSH D12.644.400.340.500 – glucagon MeSH D12.644.400.350 – gonadorelin MeSH D12.644.400.450 – motilin MeSH D12.644.400.460 – melanocyte-stimulating hormones MeSH D12.644.400.460.050 – alpha-msh MeSH D12.644.400.460.075 – beta-msh MeSH D12.644.400.460.115 – gamma-msh MeSH D12.644.400.465 – msh release-inhibiting hormone MeSH D12.644.400.470 – msh-releasing hormone MeSH D12.644.400.500 – neuropeptide y MeSH D12.644.400.525 – neurophysins MeSH D12.644.400.550 – neurotensin MeSH D12.644.400.575 – opioid peptides MeSH D12.644.400.575.180 – dynorphins MeSH D12.644.400.575.241 – endorphins MeSH D12.644.400.575.241.030 – alpha-endorphin MeSH D12.644.400.575.241.080 – beta-endorphin MeSH D12.644.400.575.241.360 – gamma-endorphin MeSH D12.644.400.575.281 – enkephalins MeSH D12.644.400.575.281.075 – enkephalin, ala(2)-mephe(4)-gly(5)- MeSH D12.644.400.575.281.231 – enkephalin, leucine MeSH D12.644.400.575.281.381 – enkephalin, methionine MeSH D12.644.400.575.281.600 – enkephalin, d-penicillamine (2,5)- MeSH D12.644.400.600 – pancreatic polypeptide MeSH D12.644.400.610 – peptide phi MeSH D12.644.400.625 – pituitary adenylate cyclase-activating polypeptide MeSH D12.644.400.640 – pituitary hormone release inhibiting hormones MeSH D12.644.400.645 – pituitary hormone-releasing hormones MeSH D12.644.400.680 – prolactin release-inhibiting hormone MeSH D12.644.400.700 – prolactin-releasing hormone MeSH D12.644.400.702 – thyrotropin-releasing hormone MeSH D12.644.400.705 – secretin MeSH D12.644.400.720 – somatostatin MeSH D12.644.400.740 – somatotropin-releasing hormone MeSH D12.644.400.800 – tachykinins MeSH D12.644.400.800.354 – eledoisin MeSH D12.644.400.800.475 – kassinin MeSH D12.644.400.800.500 – neurokinin a MeSH D12.644.400.800.550 – neurokinin b MeSH D12.644.400.800.625 – physalaemin MeSH D12.644.400.800.750 – substance p MeSH D12.644.400.875 – vasoactive intestinal peptide MeSH D12.644.400.900 – vasopressins MeSH D12.644.400.900.050 – argipressin MeSH D12.644.400.900.400 – lypressin MeSH D12.644.400.900.700 – oxytocin MeSH D12.644.400.900.900 – vasotocin
=== South East Asia === Nina Jablonski and Evelyn Nakano Glenn both assert that skin whitening in many South and Southeast Asian nations such as the Philippines grew in popularity through these nations' histories of European colonization. Multiple studies find that preferences for lighter skin in India were historically linked to both the Indian caste system and centuries of outside rule by light-skinned nations. In the Philippines and many Southeast Asian countries, lighter skin was associated with higher social status. Historians indicate that the social hierarchies in the Philippines encompasses a spectrum of skin tones due to intermarriages between indigenous populations, East Asian settlers from Japan and China, and European and American colonists.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.